Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 16 GBX
Market Cap: 65.9m GBX
Have any thoughts about
Creo Medical Group PLC?
Write Note

Creo Medical Group PLC
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Creo Medical Group PLC
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Creo Medical Group PLC
LSE:CREO
Current Portion of Long-Term Debt
ÂŁ3.5m
CAGR 3-Years
-6%
CAGR 5-Years
66%
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Current Portion of Long-Term Debt
$52m
CAGR 3-Years
-57%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Current Portion of Long-Term Debt
$22m
CAGR 3-Years
-54%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Current Portion of Long-Term Debt
ÂŁ237k
CAGR 3-Years
-24%
CAGR 5-Years
-11%
CAGR 10-Years
-24%
Angle PLC
LSE:AGL
Current Portion of Long-Term Debt
ÂŁ707k
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Current Portion of Long-Term Debt
$129.5k
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Creo Medical Group PLC
Glance View

Market Cap
65.9m GBX
Industry
Health Care

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.

CREO Intrinsic Value
25.93 GBX
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Creo Medical Group PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
3.5m GBP

Based on the financial report for Jun 30, 2024, Creo Medical Group PLC's Current Portion of Long-Term Debt amounts to 3.5m GBP.

What is Creo Medical Group PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
66%

Over the last year, the Current Portion of Long-Term Debt growth was -3%. The average annual Current Portion of Long-Term Debt growth rates for Creo Medical Group PLC have been -6% over the past three years , 66% over the past five years .

Back to Top